Psoriasiform Eruptions: An Etiological Perspective.

Am J Dermatopathol

Division of Dermatology, Tsuruse Orthopedic Clinic, Saitama, Japan.

Published: September 2023

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000002509DOI Listing

Publication Analysis

Top Keywords

psoriasiform eruptions
4
eruptions etiological
4
etiological perspective
4
psoriasiform
1
etiological
1
perspective
1

Similar Publications

The landscape of available therapeutic options for treatment of genitourinary (GU) cancers is expanding dramatically. Many of these treatments have distinct, sometimes severe, skin toxicities including morbilliform, bullous, pustular, lichenoid, eczematous, psoriasiform, and palmoplantar eruptions. Pruritus and skin pigmentation changes have also been noted.

View Article and Find Full Text PDF

Kawasaki disease (KD) is an idiopathic acute inflammatory illness that commonly affects children in Northeast Asian countries. In this case report, a psoriasiform eruption appeared on the face and extremities following the onset of KD. A review of previous reports identified 38 cases of psoriasiform eruptions following KD, typically appearing 4 days to 2 months after the onset of KD, unlike other skin manifestations associated with the disease.

View Article and Find Full Text PDF

Background: Erythroderma is a dermatologic condition characterized by widespread red and scaly skin. The causes include, but are not limited to, psoriasis, eczema, drug eruptions, pityriasis rubra pilaris (PRP), and cutaneous T-cell lymphoma. Most of these are typified by Type 2 (e.

View Article and Find Full Text PDF

Dermatoses in patients with inflammatory bowel disease under tumor necrosis factor-alpha inhibitors treatment.

Med Clin (Barc)

November 2024

Postgraduate Program in Sciences Applied to Adult Health, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address:

Introduction: Tumor necrosis factor-alpha inhibitor (anti-TNF-α) agents are essential in treating inflammatory bowel diseases (IBD). Their use, however, may cause dermatoses. This study aims to characterize the dermatoses in IBD patients on anti-TNF-α therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!